IP Library › Granted Patent US 12,329,803
Granted Patent B2
US 12,329,803 · App. 18/309,450 · Granted Jun 17, 2025

Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide

Inventor: Claudia Ania Penafuerte Diaz (Montreal, CA)
Assignee: Cura Therapeutics Inc.
A61K38/179A61P35/00C07K14/5443C07K14/55C07K14/71C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,803
App. No.
18/309,450
Granted
Jun 17, 2025
Kind
B2
Abstract

Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFβ ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of treating and/or preventing pathogenic infections.

Claims (27)

1. A method of reducing or treating fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a fusion polypeptide comprising:

an interleukin-2 (IL 2) polypeptide or a fragment thereof comprising an IL-2 receptor binding domain;

a first soluble TGFβ receptor II (sTβRII) polypeptide or a fragment thereof comprising a ligand binding domain;

and a second soluble TGFβ receptor II (sTβRII) polypeptide or a fragment thereof comprising a ligand binding domain,

thereby reducing or treating fibrosis in the subject.

2. The method of claim 1 , wherein the IL-2 polypeptide comprises SEQ ID NO: 2 or 3, or a fragment thereof comprising an IL-2 receptor binding domain.

3. The method of claim 1 , wherein the IL-2 polypeptide comprises an amino acid sequence having greater than about 80% sequence identity to SEQ ID NO: 2.

4. The method of claim 1 , wherein the first sTβRII polypeptide, the second sTβRII polypeptide, or both, comprise amino acid sequence having greater than about 80% sequence identity to SEQ ID NO: 8 or SEQ ID NO: 9.

5. The method of claim 1 , wherein the first sTβRII polypeptide, the second sTβRII polypeptide, or both, bind a TGFβ1 polypeptide, a TGFβ2 polypeptide, a TGFβ3 polypeptide, or any combination thereof.

6. The method of claim 1 , wherein the first sTβRII polypeptide and the second sTβRII polypeptide bind a TGFβ1 polypeptide.

7. The method of claim 1 , wherein the fusion polypeptide comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 10-25.

8. The method of claim 1 , wherein the administering comprises administering the fusion polypeptide to the subject by systemic administration.

9. The method of claim 1 , wherein the administering comprises administering the fusion polypeptide to the subject by intravenous administration.

10. The method of claim 1 , wherein the fusion polypeptide is included in a pharmaceutical composition, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients, carriers, diluents, or any combination thereof.

11. The method of claim 1 , wherein the subject is a human.

12. The method of claim 1 , wherein the IL-2 polypeptide comprises an amino acid sequence having greater than about 95% sequence identity to SEQ ID NO: 2.

13. The method of claim 1 , wherein the first sTβRII polypeptide, the second sTβRII polypeptide, or both, comprise amino acid sequence having greater than about 95% sequence identity to SEQ ID NO: 8 or SEQ ID NO: 9.

14. The method of claim 1 , wherein the fusion polypeptide comprises an amino acid sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 10-22.

15. A method of treating fibrosis in a subject in need thereof, the method comprising administering intravenously to the subject a therapeutically effective amount of a fusion polypeptide comprising an amino acid sequence having at least about 90% sequence identity to any one of SEQ ID NOs: 10-22, wherein the method reduces fibrosis in the subject.

16. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO: 12.

17. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO: 13.

18. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO: 14.

19. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO: 15.

20. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence according to SEQ ID NO: 12.

21. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence according to SEQ ID NO: 13.

22. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence according to SEQ ID NO: 14.

23. The method of claim 15 , wherein the fusion protein comprises an amino acid sequence according to SEQ ID NO: 15.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2023
From: PENAFUERTE DIAZ, CLAUDIA ANIA
To: CURA THERAPEUTICS, INC.
Reel/Frame 063491/0106 →
Continuity (3)
Division 17673691 · Feb 16, 2022
Provisional Application 63150450 · Feb 17, 2021
Related Publication 20230364186A1 · Nov 16, 2023
References Cited (50)
US 8283449B2 · Galipeau et al. · 2012 [cited by applicant]
US 8574548B2 · O'connor-mccourt et al. · 2013 [cited by applicant]
US 11672844B2 · Penafuerte Diaz · 2023 [cited by applicant]
US 20110150828A1 · Galipeau et al. · 2011 [cited by applicant]
US 20180155439A1 · Galipeau et al. · 2018 [cited by applicant]
US 20220127332A1 · Penafuerte Diaz · 2022 [cited by applicant]
US 20220257712A1 · Penafuerte Diaz · 2022 [cited by applicant]
EP 3260470A1 · 2017 [cited by applicant]
WO 2009152610A1 · 2009 [cited by applicant]
WO 2016200881A1 · 2016 [cited by applicant]
WO 2020047299A1 · 2020 [cited by applicant]
WO 2020047473A1 · 2020 [cited by applicant]
WO 2021041886A1 · 2021 [cited by applicant]
WO 2021096275A1 · 2021 [cited by applicant]
WO 2022086988A1 · 2022 [cited by applicant]
WO 2022178033A1 · 2022 [cited by applicant]
International Search Report and Written Opinion for Patent Application No. PCT/US2021/055646, mailed on Jan. 11, 2022, 11 pages. [cited by applicant]
International Search Report and Written Opinion for Patent Application No. PCT/US2022/016662, mailed on May 13, 2022, 17 pages. [cited by applicant]
Office Action received in U.S. Appl. No. 17/574,479, mailed on Jun. 10, 2022, 7 pages. [cited by applicant]
Restriction Requirement received in U.S. Appl. No. 17/574,479, mailed on Apr. 15, 2022, 12 pages. [cited by applicant]
Restriction Requirement received in U.S. Appl. No. 17/574,479, mailed on Mar. 7, 2022, 8 pages. [cited by applicant]
Cesana et al. (May 2007) “Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes but Does Not Affect Prognosis”, Annals of Surgical Oncology,… [cited by applicant]
Dammeijer et al. (Jun. 2017) “Rationally Combining Immunotherapies to Improve Efficacy of Immune Checkpoint Blockade in Solid Tumors”, Cytokine & Growth Factor Reviews, 36:5-15. [cited by applicant]
Dong et al. (Jan. 2007) “The Type III TGF-beta Receptor Suppresses Breast Cancer Progression”, Journal of clinical investigation, 117(1):206-217. [cited by applicant]
Frieman et al. (Apr. 8, 2004) “SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism”, PLOS Pathogens, 6(4):e1000849 (14 pages). [cited by applicant]
Heldin et al. (Aug. 2016) “Signaling Receptors for TGF-β Family Members”, Cold Spring Harbor Perspectives in Biology, 8(8):1-33. [cited by applicant]
Jamilloux et al. (Jul. 2020) “Should We Stimulate or Suppress Immune Responses in Covid-19? Cytokine and Anti-cytokine Interventions”, Autoimmunity Reviews, 19(7):102567 (14 pages). [cited by applicant]
Kim et al. (Aug. 2012) “TGF-Beta Sensitivity is Determined by N-linked Glycosylation of the Type II TGF-Beta Receptor.”, Biochemical Journal, 445(3):403-411. [cited by applicant]
Kint et al. (Dec. 1, 2015) “Infectious Bronchitis Coronavirus Inhibits STAT1 Signaling and Requires Accessory Proteins for Resistance to Type I Interferon Activity”, Journal of Virology, 89(23):12047-12057. [cited by applicant]
Kopecky-Bromberg et al. (Jan. 2007) “Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists”, Journal of Virology, 81 (2):548-557. [cited by applicant]
Malek et al. (Sep. 2004) “Tolerance, not Immunity, Crucially Depends on IL-2”, Nature Reviews Immunology, 4(9):665-674. [cited by applicant]
Marabondo et al. (Dec. 2017) “High-dose Interleukin-2 (IL-2) for the Treatment of Melanoma: Safety Considerations and Future Directions”, Expert Opinion on Drug Safety, 16(12):1347-1357. [cited by applicant]
Massague, J. (Sep. 20, 2012) “TGFBeta Signaling in Context”, Nature Reviews Molecular Cell Biology, 13:616-630. [cited by applicant]
Mendy et al. (Jun. 27, 2020) “Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients”, medRxiv, 24 pages. [cited by applicant]
Muraoka et al. (Jun. 2002) “Blockade of TGF-beta Inhibits Mammary Tumor Cell Viability, Migration, and Metastases”, Journal of Clinical Investigation, 109(12):1551-1559. [cited by applicant]
Penafuerte et al. (Mar. 1, 2012) “B Effector Cells Activated by a Chimeric Protein Consisting of IL-2 and the Ectodomain of TGF-β Receptor II Induce Potent Antitumor Immunity”, Cancer Research, 72(5):1210-1220. [cited by applicant]
Penafuerte et al. (Mar. 2012) “Fist, a Sword and Shield Fusokine for Cancer Immunotherapy”, Oncoimmunology, 1(2):224-226. [cited by applicant]
Penafuerte et al. (Jun. 15, 2011) “Novel TGF-Beta Antagonist Inhibits Tumor Growth and Angiogenesis by Inducing IL-2 Receptor-Driven STATI Activation”, Journal of Immunology, 186(12):6933-6944. [cited by applicant]
Penafuerte et al. (Dec. 1, 2009) “The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Fusion Protein Induces Potent Ex vivo Natural Killer Cell Activation and Maturation”, Cancer Res… [cited by applicant]
Rafei et al. (Mar. 1, 2007) “A GMCSF and IL-15 Fusokine Leads to Paradoxical Immunosuppression in Vivo via Asymmetrical JAK/STAT Signaling through the IL-15 Receptor Complex”, Blood, 109(5):2234-2242. [cited by applicant]
Spolski et al. (Oct. 2018) “Biology and Regulation of IL-2: From Molecular Mechanisms to Human Therapy”, Nature Reviews Immunology, 18(10):648-659. [cited by applicant]
Stauber et al. (Feb. 13, 2006) “Crystal Structure of the IL-2 Signaling Complex: Paradigm for a Heterotrimeric Cytokine Receptor”, Proceedings of the National Academy of Sciences of the United States of America, 103 (8)… [cited by applicant]
Totura et al. (Jun. 2012) “SARS Coronavirus Pathogenesis: Host Innate Immune Responses and Viral Antagonism of Interferon”, Current Opinion in Virology, 2(3):264-275. [cited by applicant]
Tzai et al. (May-Jun. 1998) “Antisense Oligonucleotide Specific for Transforming Growth Factor-beta 1 Inhibit Both In Vitro and In Vivo Growth of MBT-2 murine Bladder Cancer”, Anticancer Research, 18(3A):1585-1599. [cited by applicant]
Wang et al. (Feb. 2006) “An Oncolytic Adenovirus Expressing Soluble Transforming Growth Factor-beta Type II Receptor for Targeting Breast Cancer: In Vitro Evaluation”, Molecular cancer therapeutics, 5(2):367-373. [cited by applicant]
Wrangle et al. (Feb. 1, 2018) “IL-2 and Beyond in Cancer Immunotherapy”, Journal of Interferon & Cytokine Research, 38(2):45-68. [cited by applicant]
Yakymovych et al. (Aug. 7, 2002) “Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase”, Bioch… [cited by applicant]
Zhang et al. (Nov. 1, 1999) “Interleukin 2 Receptor Signaling Regulates the Perforin Gene through Signal Transducer and Activator of Transcription (Stat)5 Activation of Two Enhancers”, Journal of Experimental Medicine, … [cited by applicant]
Zwaagstra et al. (Jul. 2012) “Engineering and Therapeutic Application of Single-chain Bivalent TGF-beta Family Traps”, Molecular Cancer Therapeutics, 11(7):1477-1487. [cited by applicant]
Ng et al. (Oct. 1, 2016) “Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein”, Cancer Research, 76(19):5683-5695. [cited by applicant]